Revenue and Profitability - Revenue for Q3 2024 was CNY 2,329,115,080.76, a decrease of 15.04% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was CNY 30,479,245.32, an increase of 2,035.13% year-on-year[2] - Year-to-date net profit attributable to shareholders reached CNY 102,463,641.21, reflecting a significant increase of 266.29% compared to the previous year[2] - Total operating revenue for Q3 2024 was approximately CNY 7.56 billion, a decrease of 5.2% from CNY 7.97 billion in Q3 2023[15] - Net profit for Q3 2024 was approximately CNY 146.44 million, compared to CNY 50.38 million in Q3 2023, representing a significant increase of 190.5%[16] - The company reported a total profit of approximately CNY 222.98 million for Q3 2024, compared to CNY 127.08 million in Q3 2023, reflecting a year-over-year increase of 75.4%[16] - The total profit for the first three quarters of 2024 was CNY 138,808,543.58, a decrease of 57.5% compared to CNY 326,774,380.40 in 2023[23] Earnings Per Share - Basic earnings per share for Q3 2024 was CNY 0.018, up 1,700.00% from the same period last year[3] - Basic and diluted earnings per share for Q3 2024 were both CNY 0.060, up from CNY 0.016 in Q3 2023[17] Assets and Liabilities - Total assets as of the end of the reporting period were CNY 21,706,791,241.09, representing a 3.58% increase from the end of the previous year[3] - As of September 30, 2024, current assets totaled RMB 8,673,534,666.03, an increase from RMB 8,017,591,063.58 at the end of 2023, representing an increase of approximately 8.2%[11] - Total liabilities amounted to RMB 15,101,207,705.84, compared to RMB 14,686,289,888.70 at the end of 2023, marking an increase of about 2.8%[13] - The company's total assets reached RMB 21,706,791,241.09, up from RMB 20,956,700,067.79, indicating a growth of approximately 3.6%[13] - The total liabilities rose to 13,215,984,063.55 CNY, compared to 11,596,014,561.77 CNY, indicating an increase of approximately 14%[20] Cash Flow - The net cash flow from operating activities for the year-to-date period increased by 78.26% to CNY 1,058,395,635.41[5] - Cash flow from operating activities for the first nine months of 2024 was approximately CNY 1.06 billion, compared to CNY 593.73 million in the same period of 2023, indicating a substantial improvement[17] - The cash flow from financing activities generated a net inflow of 279,341,087.34 CNY, a turnaround from a net outflow of -305,232,319.28 CNY in the previous year[18] - The company recorded a net cash outflow from investing activities of CNY -86,530,136.15 in 2024, compared to a net inflow of CNY 265,246,558.21 in 2023[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 80,230[6] - Major shareholders include Jizhong Energy Co., Ltd. with a 24.08% stake and Huabei Pharmaceutical Group Co., Ltd. with a 19.90% stake[7] Cost Management - The company implemented cost control measures, leading to a reduction in procurement costs and improved profitability[5] - Total operating costs decreased to approximately CNY 7.40 billion, down 5.9% from CNY 7.86 billion in the same period last year[15] - Sales expenses decreased to approximately CNY 1.05 billion, down 21.6% from CNY 1.34 billion in Q3 2023[15] - The company reported a decrease in sales expenses to CNY 402,179,650.16 in 2024, down 33.3% from CNY 603,321,346.48 in 2023[22] Research and Development - Research and development expenses increased to approximately CNY 251.67 million, up 22.5% from CNY 205.36 million in Q3 2023[15] - Research and development expenses increased to CNY 48,995,831.25 in 2024, up 24.5% from CNY 39,246,045.74 in 2023[22] Other Financial Metrics - The company reported non-recurring gains of CNY 2,273,195.66 for Q3 2024, contributing to overall profitability[4] - Tax expenses for Q3 2024 were approximately CNY 76.54 million, slightly down from CNY 76.70 million in Q3 2023[16] - Other comprehensive income after tax for Q3 2024 was a loss of CNY 150,201.56, compared to a gain of CNY 1.61 million in Q3 2023[16]

证券代码：600812 股票简称：华北制药 编号：临 2024-057 华北制药股份有限公司 第十一届监事会第十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 华北制药股份有限公司（以下简称"公司"）第十一届监事会第十二 次会议于 2024 年 10 月 23 日向全体监事以书面和电子邮件形式发出会议 通知，以现场表决方式于 2024 年 10 月 25 日在公司会议室召开。本次会 议应出席监事 5 名，实际出席监事 5 名，会议由吕伟先生主持。会议的召 集、召开和表决程序符合《公司法》等法律、行政法规、部门规章、规范 性文件和《公司章程》的规定。 二、监事会会议审议情况 会议审议并以书面表决方式通过了以下议案： （一）审议通过《2024 年第三季度报告》 2024 年 10 月 25 日 2 根据《上海证券交易所股票上市规则（2024年4月修订）》《上海证券 交易所上市公司自律监管指南第1号--公告格式》附件《第五十二号 上市 公司季度报告》和《上海证券交易所关于做好主板上市公司20 ...

重要内容提示： 投资者可于2024年10月14日(星期一)16:00前将需要了解和关注的问题通过电 子邮件的形式发送至公司邮箱：ncpcdshbgs@163.com。公司将在本次活动上对投资者普 遍关注的问题进行回答。 华北制药股份有限公司（以下简称"公司"）已于2024年8月14日在上 海证券交易所网站（www.sse.com.cn）披露了公司《2024年半年度报告》。 为进一步加强与投资者的互动交流，公司将参加由河北证监局、河北上市 公司协会与深圳市全景网络有限公司联合举办的"2024 年度河北辖区上市 公司投资者网上集体接待日暨2024年半年报业绩说明会活动"（以下简称 "本次活动"），就投资者普遍关心的问题进行交流。 一、说明会类型 本次活动以网络互动形式召开，公司将就2024年半年度业绩、公司治 1 会议召开时间：2024年10月15日(星期二)下午15:30-17:00 会议召开地点："全景路演"网站 (http://rs.p5w.net) 会议召开方式：网络远程线上方式 证券代码：600812 证券简称：华北制药 编号：临 2024-055 华北制药股份有限公司 关于参加 2024 年河北辖区上 ...

证券代码：600812 股票简称：华北制药 编号：临 2024-054 华北制药股份有限公司 关于为下属子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 被担保人名称：华北制药金坦生物技术股份有限公司（以下简称"金坦公司"） 系公司控股子公司。 本次担保金额及已实际为其提供的担保余额：本次为金坦公司提供连带责任保 证担保，担保金额为 7,000 万元。截至本公告披露日，公司已实际为金坦公司提供的 担保余额为 54,090.54 万元。（含本次） 本次担保是否有反担保：否。 对外担保逾期的累计数量：公司为石家庄焦化集团有限责任公司担保人民币 9,000 万元，截止公告日该借款已逾期。 一、担保情况概述 近日，华北制药股份有限公司（以下简称"公司"）与中国工商银行 股份有限公司石家庄和平支行（以下简称"工行和平支行"）签订了《保 证合同》，为金坦公司在工行和平支行开展的流动资金业务提供连带责任 保证担保。 单位：万元 | 序 | 被担保 | | | | 本次提供担保前 | | 本次提供担保后 | ...

证券代码：600812 股票简称：华北制药 编号：临 2024-053 华北制药股份有限公司 关于下属公司获得《药品注册证书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，华北制药股份有限公司（以下简称："公司"）下属控股子公 司华北制药华坤河北生物技术有限公司（以下简称："华坤公司"）收到 国家药品监督管理局核准签发的恩曲他滨丙酚替诺福韦片（II） （200mg/25mg）《药品注册证书》，现将有关情况公告如下： 一、药品注册证书的主要内容 | 药物名称 | 恩曲他滨丙酚替诺福韦片（II） | | --- | --- | | 英文名/拉丁名 | Emtricitabine and Tenofovir Alafenamide Fumarate Tablets（Ⅱ） | | 受理号 | CYHS2300939 | | 证书编号 | 2024S02210 | | 剂型 | 片剂 | | 申请事项 | 药品注册（境内生产） | | 注册分类 | 化学药品 4 类 | | 规格 | 每片含 恩曲他滨，25mg 丙酚替诺 ...

证券代码：600812 股票简称：华北制药 编号：临 2024-052 华北制药股份有限公司 一、担保情况概述 近日，华北制药股份有限公司（以下简称"公司"）与交通银行股份 有限公司河北省分行（以下简称"交通银行河北省分行"）签订了《保证 合同》，为华民公司、先泰公司、华胜公司在交通银行河北省分行开展的 关于为下属子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 被担保人名称：华北制药河北华民药业有限责任公司（以下简称"华民公司"）、 华药国际医药有限公司（以下简称"华药国际"）、华北制药集团先泰药业有限公司（以 下简称"先泰公司"）、华北制药华胜有限公司（以下简称"华胜公司"）系公司全资 子公司，华北制药金坦生物技术股份有限公司（以下简称"金坦公司"）系公司控股子 公司。 本次担保金额及已实际为其提供的担保余额：本次为华民公司、华药国际、先 泰公司、华胜公司、金坦公司提供连带责任保证担保或最高额连带责任保证担保，担保 金额分别为 17,000 万元、15,000 万元（最高额）、8,000 ...

证券代码：600812 股票简称：华北制药 编号：临 2024-050 | 股东名称 | 华药集团 | | --- | --- | | 本次解除质押股份（股） | 80,000,000 | | 占其所持股份比例 | 23.43% | | 占公司总股本比例 | 4.66% | | 解除质押时间 | 2024 年 8 月 22 日 | 一、本次股份解除质押情况 1 华北制药股份有限公司 关于股东部分股份解除质押及质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 截至本公告日，公司股东华北制药集团有限责任公司（以下简称"华药集团"） 持有公司股份 341,471,645 股,占公司总股本 19.90%，华药集团本次解除质押 80,000,000 股；同日质押 80,000,000 股，占其持股总数的 23.43%，占公司总股本的 4.66%。 华药集团和一致行动人【冀中能源集团有限责任公司（以下简称"冀中能源集 团"）、冀中能源股份有限公司（以下简称"冀中能源"）】合计持有公司股份 943,698,816 ...

证券代码：600812 股票简称：华北制药 编号：临 2024-051 华北制药股份有限公司 关于下属子公司获得《药物临床试验批准通知书》的公告 三、同类药品的市场情况 截至目前，全球暂无针对诺如病毒的疫苗获批上市。国外由 Takda 研 发的双价诺如病毒疫苗是最早报告临床疗效的候选疫苗，目前由 Takda 转 至 Hillevax 继续开发。此外，Vaxart 基于腺病毒载体研发了经口服的单/ 双价诺如病毒疫苗，Moderna TX 研发的五价（mRNA-1405）和三价 （mRNA-1403）诺如病毒候选疫苗也已经进入 I 期临床阶段。目前国内已进 入临床试验阶段的四价重组诺如病毒疫苗有 3 家，金坦公司的四价重组诺 如病毒疫苗价型与其余两家公司不完全相同，因此可以起到不同的保护效 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2024 年 8 月 22 日，华北制药股份有限公司（以下简称"公司"）下 属控股子公司华北制药金坦生物技术股份有限公司（以下简称"金坦公司"） 收到国家药品监督管理局核准签发的四价重组诺如病毒疫 ...

华北之鸟的党委常委总会计师以及董事会秘书肖志广肖总正在杨静杨总以及爱儿主管这个罗嘉楠罗总来跟大家一起交流一下公司上半年的情况我是试问的医药分析师张静涵那今天跟我一起在线主持的还有我们组的于玉军 那我们也看到了华北制药的这个中报已经披露了那公司上半年是在整个的这个经营业绩尤其是利润这块取得了一个非常大的这样的一个进步那我们接下来就先有请肖总跟大家把上半年的情况做一个介绍然后后面我们进入到这个问答的环节有请肖总好的静涵各位投资者我来介绍一下华药上半年的情况 从大家看到的这个中报里边的数据啊再重复一下吧包括期内呢我们公司的整体实现营业收入是52.31亿元比基本上持平吧略有降低那么一丢丢归属于上市公司股东的净利润是实现了7198.44万元比这个业绩预告还是略略多了那么不到200万吧预告是7000万左右 同比是增加171%去年同期这个数呢是2655万是有一个比较大的增长归属于上市公司股东扣飞后的这个净利润是5434.98万元预告呢是5200万左右也是略增同比呢是增加了5329万去年只有106万去年这个基数是比较小增幅比较大 现在可能也在各种新闻里面看到有些标题提高的比例较大实际上总金额没那么大主要是基数太低我们认为现在 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥5,231,120,589.63, a slight decrease of 0.04% compared to ¥5,233,404,242.63 in the same period last year[15]. - Net profit attributable to shareholders increased significantly to ¥71,984,395.89, representing a 171.17% increase from ¥26,545,580.14 in the previous year[15]. - The net cash flow from operating activities reached ¥883,182,799.92, up 233.30% from ¥264,985,100.37 in the same period last year[15]. - The basic earnings per share rose to ¥0.042, a 180.00% increase compared to ¥0.015 in the previous year[16]. - The total assets of the company at the end of the reporting period were ¥21,751,363,712.71, reflecting a 3.79% increase from ¥20,956,700,067.79 at the end of the previous year[15]. - The net assets attributable to shareholders increased to ¥5,331,865,791.35, a 0.31% rise from ¥5,315,303,557.08 at the end of the previous year[15]. - The weighted average return on net assets increased by 0.84 percentage points to 1.34%[16]. - The company reported a significant increase in net profit after deducting non-recurring gains and losses, reaching ¥54,349,775.94, compared to ¥1,058,954.77 in the previous year, marking a 5,032.40% increase[15]. - The diluted earnings per share also increased to ¥0.042, reflecting the company's improved profitability[16]. Market Position and Product Development - The company has over 700 product specifications, including antibiotics and biopharmaceuticals, maintaining a leading position in production scale and product quality in China[19]. - The company is recognized for its traditional advantages in the antibiotic sector, with a complete product chain from raw materials to formulations[22]. - The company has established a national key laboratory for antibody drug research, positioning itself as a leader in biopharmaceutical technology in China[22]. - The company is actively expanding its market presence in biopharmaceuticals while consolidating its position in chemical pharmaceuticals and health consumer products[19]. - The company has made significant progress in R&D, with ten products, including injectable sulbactam sodium, submitted for review, and three products approved for consistency evaluation[25]. - The company is focusing on developing new treatment areas such as cardiovascular diseases, kidney diseases, and diabetes, aiming to create a product cluster with competitive advantages[24]. Environmental Compliance and Management - The company reported a total of 13 key pollutant discharge units, with specific wastewater discharge limits and actual discharge concentrations provided[45]. - The actual chemical oxygen demand discharge was 213.680 mg/L against a limit of 300 mg/L, and ammonia nitrogen discharge was 6.036 mg/L against a limit of 15 mg/L[45]. - The company has established 8 sets of waste gas treatment facilities, effectively managing emissions from fermentation and process waste gases[53]. - The company’s environmental monitoring data indicates compliance with discharge limits for various pollutants[46]. - The company has established emergency response plans for sudden environmental incidents, ensuring preparedness[60]. - The company’s wastewater discharge is directed to the Shijiazhuang Wastewater Treatment Company after meeting standards, with one total wastewater discharge outlet[107]. - The company has implemented various environmental protection measures, including regular inspections and the establishment of a pollution prevention system, enhancing its environmental management level[115]. Corporate Governance and Management Changes - The company held its first extraordinary general meeting on April 23, 2024, where the election of the 11th board of directors was approved, including Mr. Wang Lixin and Mr. Xiao Zhiguang as directors, and Mr. Shi Yingzhe as an independent director[36]. - There were significant changes in senior management, with multiple resignations including the chairman and general manager, and new appointments including Mr. Wang Lixin as the general manager[39]. - The company is actively managing its governance structure with the election of new board members and management personnel[39]. Related Party Transactions and Financial Commitments - The company expects to incur a total of 865.2 million CNY in daily related party transactions for 2024, with 38.6 million CNY already realized by June 30[123]. - The company has committed to not engaging in any business that competes with Huabei Pharmaceutical, ensuring a focus on pharmaceutical logistics trade[120]. - The total amount of guarantees provided by the company, including those to subsidiaries, is 2,038.75 million RMB, which accounts for 31.02% of the company's net assets[129]. - The company has guaranteed 900 million RMB for Shijiazhuang Coking Group Co., Ltd., which is currently overdue[130]. Financial Reporting and Accounting Policies - The company’s financial statements are prepared based on the assumption of going concern, with no significant doubts about its ability to continue operations in the next 12 months[164]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that its financial reports reflect a true and complete picture of its financial status and operating results[165]. - The company recognizes expected credit losses for financial assets measured at amortized cost, ensuring prudent risk management[179]. - The company uses observable inputs for fair value measurement of financial instruments in active markets, and when not available, applies valuation techniques using unobservable inputs[184].